Moreover, considering the problem of the decline in IFN response with continued STING activation, it has been proposed that a subset of patients might benefit from inhibiting the cGAS-STING pathway to control tumor –induced chronic inflammation and the resulting immune suppression (characterized by high cGAS and low STING levels) [164]. This evidence concerns the gene CGAS and neoplasm.